Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25025995 | 0.86 | ALDH1A1 (0.39) | ALDH1A1KMT2AKDM4EGAAL3MBTL1 | |
| SCHEMBL22445819 | 0.73 | PDK1 (0.48) | ALDH1A1KMT2AKDM4EGAAL3MBTL1 | |
| SCHEMBL25025992 | 0.72 | KDM4E (0.46) | ALDH1A1KMT2AKDM4EGAAMEN1 | |
| SCHEMBL5102185 | 0.72 | KDM4E (0.44) | ALDH1A1KMT2AKDM4EGAAMEN1 | |
| SCHEMBL259951 | 0.71 | ALDH1A1 (0.52) | ALDH1A1KMT2AKDM4EGAAMEN1 | |
| SCHEMBL16836044 | 0.71 | KDM4E (0.56) | ALDH1A1KMT2AKDM4EGAALMNA | |
| SCHEMBL30047263 | 0.71 | ALDH1A1 (0.52) | ALDH1A1KMT2AKDM4EGAAMEN1 | |
| SCHEMBL7898049 | 0.70 | CYP2C19 (0.47) | ALDH1A1KMT2AKDM4EGAAL3MBTL1 | |
| SCHEMBL25554164 | 0.70 | GAA (0.33) | ALDH1A1KDM4EGAAL3MBTL1LMNA | |
| SCHEMBL25554172 | 0.69 | KMT2A (0.43) | ALDH1A1KMT2AKDM4EGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A1 4654/4885KMT2A 3772/4885KDM4E 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.